Patents by Inventor Olav Benjamin Ryan

Olav Benjamin Ryan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9827336
    Abstract: A tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand comprising four HOPO moieties and the ion of an alpha-emitting thorium radionuclide, where at least one of the four HOPO moieties is substituted at the N-position with a hydroxyalkyl solubilising group.
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: November 28, 2017
    Assignee: BAYER AS
    Inventors: Hanne Therese Bonge-Hansen, Olav Benjamin Ryan
  • Publication number: 20150147272
    Abstract: A tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand comprising four HOPO moieties and the ion of an alpha-emitting thorium radionuclide, where at least one of the four HOPO moieties is substituted at the N-position with a hydroxyalkyi solubilising group and wherein the tissue targeting moiety has binding affinity for the CD33 receptor. A corresponding pharmaceutical formulation and method and use in treatment, as well as methods of manufacture are provided.
    Type: Application
    Filed: May 13, 2013
    Publication date: May 28, 2015
    Inventors: Hanne Therese Bonge-Hanssen, Olav Benjamin Ryan
  • Publication number: 20150110817
    Abstract: A tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand comprising four HOPO moieties and the ion of an alpha-emitting thorium radionuclide, where at least one of the four HOPO moieties is substituted at the N-position with a hydroxyalkyl solubilising group.
    Type: Application
    Filed: May 13, 2013
    Publication date: April 23, 2015
    Inventors: Hanne Therese Bonge-Hansen, Olav Benjamin Ryan
  • Publication number: 20150104385
    Abstract: A tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand comprising four HOPO moieties and the ion of an alpha-emitting thorium radionuclide, where at least one of the four HOPO moieties is substituted at the N-position with a hydroxyalkyl solubilising group and wherein the tissue targeting moiety has binding affinity for the CD22 receptor. Methods of treatment utilising such complexes and methods of formation of such complexes are provided.
    Type: Application
    Filed: May 13, 2013
    Publication date: April 16, 2015
    Applicant: Algeta ASA
    Inventors: Hanne Therese Bonge-Hansen, Olav Benjamin Ryan